Search results
- 21.46Add to watchlist+0.34 (+1.61%)As of Fri. May 3, 2024 1:17 PM EDT · Delayed Quote (USD) · Market open
- Open21.35High21.47Low21.24
- Mkt CapN/AP/E (TTM)9.03Div & Yield1.25 & 5.92%
- Prev. Close21.1252 Wk. Low18.2052 Wk. High22.80
Related stocks
Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease ( EC 3.4.21.68) found on endothelial cells lining the blood vessels.
Oct 6, 2023 · Eligibility. Timeframe for Use. Side Effects. Getting Treatment. Tissue plasminogen activator (tPA) is a drug given through a vein to help break up a blood clot so that blood flow can return to normal. It is used for the emergency treatment of ischemic stroke, which occurs when a blood clot interrupts blood flow to a region of the brain.
Feb 20, 2023 · Continuing Education Activity. Tissue plasminogen activator (tPA) is classified as a serine protease (enzymes that cleave peptide bonds in proteins). It is thus one of the essential components of the dissolution of blood clots. Its primary function includes catalyzing the conversion of plasminogen to plasmin, the primary enzyme involved in ...
Known by the generic name alteplase and marketed as Activase® (Genentech), tPA is given to patients through an IV in the arm, and it works by dissolving blood clots that block blood flow to the brain.
Mechanism of action. Regulation and inhibition. History. Society and culture. Legal status. Economics. Brand names. Controversies. References. Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA).
